dapsone has been researched along with Central Nervous System Toxoplasmosis in 16 studies
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 9.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
" We report here an unusual case of relapse of toxoplasmic encephalitis in an HIV-infected patient, possibly due to a drug-to-drug interaction between dapsone and minocycline." | 7.75 | Drug-to-drug interaction between dapsone and minocycline: an unusual cause of relapse of toxoplasmic encephalitis in an HIV-infected patient. ( Bigé, N; Gallien, S; Gervais, A; Kitzis, MD; Leport, C; Longuet, P, 2009) |
"Dapsone was more effective in the primary prophylaxis of toxoplasmic encephalitis, with six toxoplasmic encephalitis events occurring among those receiving aerosolized pentamidine, compared to none among those taking dapsone (p = 0." | 6.67 | Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. ( Barr, M; Carlo, C; Chanin, E; Gregory, G; Kiely, S; Martin, M; Thorn, M; Thornton, J; Torres, RA, 1993) |
"We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial." | 5.09 | Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. ( Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Grillo, R; Murri, R; Pallavicini, F; Pezzotti, P, 2001) |
"To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 5.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
" We report here an unusual case of relapse of toxoplasmic encephalitis in an HIV-infected patient, possibly due to a drug-to-drug interaction between dapsone and minocycline." | 3.75 | Drug-to-drug interaction between dapsone and minocycline: an unusual cause of relapse of toxoplasmic encephalitis in an HIV-infected patient. ( Bigé, N; Gallien, S; Gervais, A; Kitzis, MD; Leport, C; Longuet, P, 2009) |
"Dapsone was more effective in the primary prophylaxis of toxoplasmic encephalitis, with six toxoplasmic encephalitis events occurring among those receiving aerosolized pentamidine, compared to none among those taking dapsone (p = 0." | 2.67 | Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. ( Barr, M; Carlo, C; Chanin, E; Gregory, G; Kiely, S; Martin, M; Thorn, M; Thornton, J; Torres, RA, 1993) |
"We describe the course of 36 AIDS patients with cerebral toxoplasmosis and present a review of clinical signs, diagnosis, therapy, and survival times." | 1.31 | [HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients]. ( Evers, S; Fischer, A; Freund, M; Grüneberg, U; Happe, S; Heese, Ch; Husstedt, IW; Kloska, S; Reichelt, D, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 13 (81.25) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gallien, S | 1 |
Bigé, N | 1 |
Kitzis, MD | 1 |
Longuet, P | 1 |
Gervais, A | 1 |
Leport, C | 1 |
Happe, S | 1 |
Fischer, A | 1 |
Heese, Ch | 1 |
Reichelt, D | 1 |
Grüneberg, U | 1 |
Freund, M | 1 |
Kloska, S | 1 |
Evers, S | 1 |
Husstedt, IW | 1 |
Katlama, C | 1 |
Opravil, M | 3 |
Pechère, M | 2 |
Lazzarin, A | 2 |
Heald, A | 2 |
Rüttimann, S | 2 |
Iten, A | 2 |
Furrer, H | 1 |
Oertle, D | 2 |
Praz, G | 2 |
Vuitton, DA | 1 |
Hirschel, B | 1 |
von Overbeck, J | 1 |
Oksenhendler, E | 1 |
Charreau, I | 1 |
Tournerie, C | 1 |
Azihary, M | 1 |
Carbon, C | 1 |
Aboulker, JP | 1 |
Torres, RA | 1 |
Barr, M | 1 |
Thorn, M | 1 |
Gregory, G | 1 |
Kiely, S | 1 |
Chanin, E | 1 |
Carlo, C | 1 |
Martin, M | 1 |
Thornton, J | 1 |
Tocchetti, A | 1 |
Tambini, R | 1 |
Allegro, A | 1 |
Longoni, E | 1 |
Rinaldi, E | 1 |
Joos, B | 1 |
Lüthy, R | 1 |
Mallolas, J | 2 |
Zamora, L | 2 |
Gatell, JM | 2 |
Miró, JM | 1 |
Vernet, E | 1 |
Valls, ME | 1 |
Soriano, E | 1 |
SanMiguel, JG | 1 |
Girard, PM | 1 |
Landman, R | 1 |
Gaudebout, C | 2 |
Olivares, R | 1 |
Saimot, AG | 1 |
Jelazko, P | 1 |
Certain, A | 1 |
Boué, F | 1 |
Bouvet, E | 1 |
Richards, FO | 1 |
Kovacs, JA | 1 |
Luft, BJ | 1 |
Antinori, A | 2 |
Murri, R | 2 |
Ammassari, A | 2 |
De Luca, A | 2 |
Linzalone, A | 1 |
Cingolani, A | 2 |
Damiano, F | 1 |
Maiuro, G | 1 |
Vecchiet, J | 1 |
Scoppettuolo, G | 1 |
Garavelli, PL | 1 |
Pezzotti, P | 1 |
Pallavicini, F | 1 |
Grillo, R | 1 |
1 review available for dapsone and Central Nervous System Toxoplasmosis
Article | Year |
---|---|
Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Cats; Dapsone; Drug Therapy, | 1995 |
8 trials available for dapsone and Central Nervous System Toxoplasmosis
Article | Year |
---|---|
Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virus.
Topics: Adult; CD4 Lymphocyte Count; Dapsone; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma | 1995 |
Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Animals; Dapsone; Drug Adm | 1995 |
Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; | 1993 |
Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Therapy, Combination; Female; Follow-Up | 1994 |
Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Topics: Adult; Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Dapsone; Drug Therapy, Co | 1993 |
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Topics: Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Dapsone; Drug Combinations; Ence | 1993 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
Topics: Adult; Animals; Anti-Infective Agents; Bacterial Infections; Dapsone; Encephalitis; Female; HIV Infe | 2001 |
7 other studies available for dapsone and Central Nervous System Toxoplasmosis
Article | Year |
---|---|
Drug-to-drug interaction between dapsone and minocycline: an unusual cause of relapse of toxoplasmic encephalitis in an HIV-infected patient.
Topics: Adult; Dapsone; Drug Interactions; Encephalitis; HIV Infections; HIV-1; Humans; Male; Minocycline; R | 2009 |
[HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Antiretrovir | 2002 |
[The impact of the prevention of cerebral toxoplasmosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Brain Abs | 1995 |
Toxoplasma gondii infection in advanced HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; Middle Ag | 1994 |
Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Adult; Aged; Dapsone; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Phenotyp | 1994 |
Prophylaxis of pneumocystis pneumonia and toxoplasmosis.
Topics: Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Humans; Pneumonia, Pneumocystis; Pyrimeth | 1996 |
[Dapsone in the prevention of HIV-related parasitosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiparasitic Agents; Dapsone; Drug Therapy, Combinati | 1996 |